Hormonal
Treatment with the GLP-1 receptor agonist liraglutide (1.2 mg/day) prevents bone mineral content loss and increases bone formation markers in obese women who have maintained significant weight loss.
If you are an obese woman who has successfully lost weight and kept it off, ask your doctor about GLP-1 medications like liraglutide. This study shows that this medication can protect your bones from the typical loss that happens after weight loss, likely by boosting bone formation markers.
Treatment with a long-acting GLP-1 RA increased bone formation by 16% and prevented bone loss after weight loss obtained through a low calorie-diet, supporting its role as a safe weight-lowering agent.
Why this rating
Randomized controlled trial with a relatively small sample size (n=37) but rigorous design and clear statistical significance.
Source
GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women
Eva W. Iepsen et al. · The Journal of Clinical Endocrinology & Metabolism · 2015
DOI 10.1210/jc.2015-1176
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →